The case for & against
Bull & Bear analysis
QT Imaging Holdings, Inc. (NASDAQ: QTI) is an innovative company specializing in breast imaging solutions, notably through its state-of-the-art Breast Acoustic CT scanner technology. Positioned as a key player in advancing women's healthcare, QT Imaging addresses significant limitations posed by traditional imaging methods while aiming to enhance clinical outcomes and patient experiences. With strategic growth initiatives, regulatory approvals, and a focus on creating a quantitative imaging platform, QT Imaging is positioned within the evolving medical imaging market, capitalizing on trends toward non-invasive and patient-centered technologies.
Bull says
- ↑Q2 revenue $7.4 M (+103% YoY); 2026 guidance $39 M, doubling 2025 sales
- ↑Category 3 CPT reimbursement code effective Jan 2027 improves coverage
- ↑High hedge-fund 13F ownership indicates institutional confidence
- ↑Radiation- and compression-free Breast Acoustic CT offers unique edge
- ↑US direct-sales hires expand commercial infrastructure and adoption
- ↑Positive growth and balance-sheet factors support upside potential
Bear says
- ↓Q2 net loss $11.1 M vs $4.0 M YoY, straining cash reserves
- ↓Operating expenses climbed 69% YoY to $4.9 M, hurting margins
- ↓Negative profitability and high leverage signal weak financial health
- ↓Slow clinical adoption risk may delay forecasted revenue ramp
- ↓Geopolitical headwinds in Gulf markets could disrupt sales growth
- ↓Low liquidity and analyst downgrades add trading and sentiment risk
Earnings Call · Q4 2025 · Mgmt. Guidance
Transcript signals
Bull points
- We reported record revenue of $8.3 million for Q4 2025, up 877% from the prior year and up 97% versus Q3 2025. The year-over-year increase was primarily attributable to the shipment of 17 breast acoustic CT scanners during the quarter.
- Revenue was $18.9 million for 2025, exceeding the company's guidance of $18 million and representing 288% growth over 2024.
- we are affirming our expectation for revenue of approximately $39 million for the year, more than doubling 2025 revenue. This guidance is based on the expected shipment of scanners under current distributors' minimum order quantities as well as the early monetization of cloud-based services as we bring our platform online across clinical and research customers.
Bear points
- Net loss for 2025 was $21.1 million, which included other expense of $8.8 million consisting of non-cash expense of $6.6 million incurred at the issuance of the Linn Rock Lake term loan and extinguishment loss of $2.1 million for the Yorkville note and cable car note and $100,000 extension fees for the cable car note, as well as a $3.6 million increase in the fair value of warrant liability and a $1.8 million increase in the fair value of earn out liability. This compared with a net loss of $9 million for 2024.
- EBITDA for 2025 was negative $18.3 million compared with negative $4.3 million for 2024.
- All forward-looking statements are based on QT imaging's current beliefs as well as assumptions made by an information currently available to QT imaging and related to, among other things, QT imaging's breast acoustic CT scanner, including its product commercialization and manufacturing, the evolution of QT imaging into a scalable imaging platform, the QT imaging cloud platform and SAS model, performance of software enhancements, new product development and introductions, product sales growth, and projected revenues, and QT Imaging's industry and future events.